<DOC>
	<DOCNO>NCT00670384</DOCNO>
	<brief_summary>The purpose study identify effective dose allergen-specific immunotherapy short ragweed ( Ambrosia artemisiifolia ) administer oral/sublingual route .</brief_summary>
	<brief_title>Phase 2 Study Adults Sensitized Short Ragweed</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Inclusion Criteria Male female patient age 18 55 year ( inclusive . Written inform consent participate study . Documented allergy short ragweed pollen demonstrate positive epicutaneous skin test ( wheal &gt; 3 mm ) symptoms allergic rhinitis two previous short ragweed season . Female subject childbearing potential , define surgically sterile least 2 year postmenopausal , must agree use one follow form contraception screen 4 week followup period follow last dose Clinical Trial Material ( CTM ) : hormonal ( oral , implant , injection ) begin &gt; 30 day prior screen , barrier ( condom , diaphragm spermicide ) , Intrauterine Device ( IUD ) , vasectomized partner ( 6 month minimum ) . No clinically significant abnormal finding physical examination , exception head , eye , ear , nose throat ( HEENT ) finding consistent allergic rhinitis , medical history , clinical laboratory result screen , opinion Investigator , would jeopardize safety subject impact validity study result Previous allergen immunotherapy ( subcutaneous immunotherapy ( SCIT ) , oral immunotherapy , sublingual immunotherapy ( SLIT ) , recombinant peptide ) short ragweed within 24 month Screening Visit . History severe allergic reaction require medical intervention . Intolerance severe allergic reaction previous immunotherapy ( SCIT , oral immunotherapy , SLIT , recombinant peptide ) . Allergy nonantigen ingredient study drug formulation , include , limited , Food , Drug Cosmetic ( FD &amp; C ) Yellow # 5 , sodium chloride , sodium bicarbonate , glycerine . History asthma require daily medication . Subjects receive antiIgE monoclonal antibody . Congenital immune deficiency acquire immune suppression . Causes acquire immune suppression may include , limited , systemic illness malignancy infection , use medication corticosteroid chemotherapeutic agent , radiation therapy . History organ transplant , hematologic malignancy , autoimmune disease , myocardial infarction , congestive heart failure . History clinically significant gastrointestinal , renal , hepatic , neurologic , hematologic , endocrine , oncologic , pulmonary , psychiatric , cardiovascular disease , condition , opinion Investigator , would jeopardize safety subject impact validity study result . Inability unwillingness stop use drug may inhibit whealandflare reaction rhinitic response prior study duration dose CTM ( exception protocolspecified rescue medication provide study site use Study Day 0 ) . Inability unwillingness stop use drug may inhibit ability treat severe allergic adverse event . This include , limited : beta blocker atenolol ( Tenormin ) , metoprolol ( Lopressor , ToprolXL ) propranolol ( Inderal , Inderal LA ) 14 day prior Study Day 0 duration study Female subject try conceive , pregnant , lactate . Positive serum pregnancy test screen positive human chorionic gonadotropin ( HCG ) urine test Study Day 0 prior administration study drug woman childbearing potential . Positive blood screen HIV , Hepatitis B surface antigen ( HbSAg ) , Hepatitis C. History alcohol drug abuse within year prior Screening Visit , current evidence substance dependence abuse . Participation clinical trial receipt nonFDA approve therapy within 30 day prior Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>SLIT</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Short ragweed</keyword>
	<keyword>SAR</keyword>
	<keyword>Seasonal allergic rhinitis</keyword>
</DOC>